Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species

Psychopharmacology

Volumn 182, Issue 1, 2005, Pages 132-143

  Varty, G B ^a   Hyde, L A ^a   Hodgson, R A ^a   Lu, S X ^a   McCool, M F ^a   Kazdoba, T M ^a   Del Vecchio, R A ^a   Guthrie, D H ^a   Pond, A J ^a   Grzelak, M E ^a   Xu, X ^a   Korfmacher, W A ^a   Tulshian, D ^a   Parker, E M ^a   Higgins, G A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anxiety; Behavior; Guinea pig; Mouse; Nociceptin; NOP receptor; ORL 1 receptor; Rat

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 8,2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL 1 PHENYL 1,3,8 TRIAZASPIRO[4 5]DECAN 4 ONE; CHLORDIAZEPOXIDE; DIAZEPAM; HALOPERIDOL; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; NALTREXONE; NOCICEPTIN RECEPTOR AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; OPIOID RECEPTOR LIKE 1; RO 646198; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR; BODY TEMPERATURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SPECIFICITY; FEMALE; GENOTYPE; GUINEA PIG; KNOCKOUT MOUSE; LICKING; LOCOMOTION; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PUNISHMENT; RAT; ROTAROD TEST; TASK PERFORMANCE; TOXICITY TESTING; TRANQUILIZING ACTIVITY; VOCALIZATION; WALKING;

ANIMALS; ANTI-ANXIETY AGENTS; AROUSAL; BENZIMIDAZOLES; CHLORDIAZEPOXIDE; CONDITIONING, CLASSICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUINEA PIGS; IMIDAZOLES; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PIPERIDINES; RATS; RECEPTORS, OPIOID; SPECIES SPECIFICITY; SPIRO COMPOUNDS; VOCALIZATION, ANIMAL;

EID: 25844515866     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0041-4     Document Type: Article

References (40)

1. Calo G, Guerrini R, Rizzi A, Salvadori S, Regoli D (2000) Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol 129:1261-1283
2. Champion HC, Kadowitz PJ (1997) Nociceptin, an endogenous ligand for the ORL1 receptor, has novel hypotensive activity in the rat. Life Sci 60:PL241-PL245
3. Devine DP, Reinscheid RK, Monsma FJ Jr, Civelli O, Akil H (1996a) The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res 727:225-229
4. Devine DP, Taylor L, Reinscheid RK, Monsma FJ Jr, Civelli O, Akil H (1996b) Rats rapidly develop tolerance to the locomotor inhibiting effects of the novel neuropeptide orphanin FQ. Neurochem Res 21:1387-1396
5. Dorow R (1987) FG 7142 and its anxiety-inducing effects in humans. Br J Clin Pharmacol 23:781-782
6. Fernandez F, Misilmeri MA, Felger JC, Devine DP (2004) Nociceptin/orphanin FQ increases anxiety-related behavior and circulating levels of corticosterone during neophobic tests of anxiety. Neuropsychopharmacology 29:59-71
7. Gavioli EC, Rae GA, Calo G, Guerrini R, De Lima TC (2002) Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test. Br J Pharmacol 136:764-772
8. Gerlai R (1996) Gene-targetting studies of mammalian behaviour: is it the mutation or the background genotype? Trends Neurosci 19:177-181
9. Griebel G, Perrault G, Sanger DJ (1999) Orphanin FQ a novel neuropeptide with anti-stress-like activity. Brain Res 836:221-224
10. Hashiba E, Lambert DG, Jenck F, Wichmann J, Smith G (2002) Characterisation of the non-peptide nociceptin receptor agonist, Ro 64-6198 in Chinese hamster ovary cells expressing recombinant human nociceptin receptors. Life Sci 70:1719-1725
11. Higgins GA, Grottick AJ, Ballard TM, Richards JG, Messer J, Takeshima H, Pauly-Evers M, Jenck F, Adam G, Wichmann J (2001) Influence of the selective ORL1 receptor agonist, Ro 64-6198, on rodent neurological function. Neuropharmacology 41:97-107
12. Higgins GA, Kew JNC, Richards JG, Takeshima H, Jenck F, Adam G, Wichmann J, Kemp JA, Grottick AJ (2002) A combined pharmacological and genetic approach to investigate the role of orphanin FQ in learning and memory. Eur J Neurosci 15:911-922
13. Jenck F, Moreau J-L, Martin JR, Kilpatrick GJ, Reinscheid RK, Monsma FJ, Nothacker H-P, Civelli O (1997) Orphanin FQ acts as an anxiolytic to attenuate behavioural responses to stress. Proc Natl Acad Sci U S A 94:14854-14858
14. Jenck F, Wichmann J, Dautzenberg FM, Moreau J-L, Ouagazzal AM, Martin JR, Lundstrom K, Cesura AM, Poli SM, Roever S, Kolczewski S, Adam G, Kilpatrick GJ (2000) A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc Natl Acad Sci U S A 97:4938-4943
15. 2 and orphanin FQ/nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats. J Pharmacol Exp Ther 289:173-180
16. Kawamoto H, Ozaki S, Itoh Y, Miyaji M, Arai S, Nakashima H, Kato T, Ohta H, Iwasawa Y (1999) Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). J Med Chem 42:5061-5063
17. Kazdoba TM, Del Vecchio RA, Hyde LA (2003) Automated evaluation of sensitivity to foot shock in mice: inbred strain differences and analgesic effect of morphine. Soc Neurosci Abstr 29:836.18
18. Kehne JH, Coverdale S, McCloskey TC, Hoffman DC, Cassella JV (2000) Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacology 39:1357-1367
19. Kyuhou S, Gemba H (1999) Injection of orphanin FQ/nociceptin into the periaqueductal gray suppresses the forebrain-elicited vocalization in the guinea pig. Neurosci Lett 260:113-116
20. Le Pen G, Wichmann J, Moreau J-L, Jenck F (2002) The orphanin receptor agonist Ro 64-6198 does not induce place conditioning in rats. Neuroreport 13:451-454
21. Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, Mercuri NB, Rizzi A, Franchi G, Beani L, Bianchi C, Morari M (2004) Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulate stimulates nigrostriatal dopaminergic transmission and motor behaviour. J Neurosci 24:6659-6666
22. McElroy JF, Ward KA, Zeller KL, Jones KW, Gilligan PJ, He L, Lelas S (2002) The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats. Psychopharmacology 165:86-92
23. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B, Mazarguil H, Vassart G, Parmentier M, Costentin J (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532-535
24. Mogil JS, Pasternak GW (2001) The molecular and behavioural pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 53:381-415
25. Molewijk HE, Hartog K, van der Poel AM, Mos J, Olivier B (1996) Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs. Psychopharmacology 128:31-38
26. Nishi M, Houtani T, Noda Y, Mamiya T, Sato K, Doi T, Kuno J, Takeshima H, Nukuda T, Nabeshima T, Yamashita T, Noda T, Sugimoto T (1997) Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/ orphanin FQ receptor. EMBO J 16:1858-1864
27. Olivier B, Molewijk E, van Oorschot R, van der Heyden J, Ronken E, Mos J (1998) Rat pup ultrasonic vocalization: effects of benzodiazepine receptor ligands. Eur J Pharmacol 358:117-128
28. Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Azuma T, Ichikawa D, Nambu H, Iguchi T, Iwasawa Y, Ohta H (2000) In vitro and in vivo pharmacological characterisation of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur J Pharmacol 402:45-53
29. Pomonis JD, Billington CJ, Levine AS (1996) Orphanin FQ, agonist of orphan receptor ORL1, stimulates feeding in rats. Neuroreport 8:369-371
30. Recker MD, Higgins GA (2004) The ORL-1 receptor agonist, Ro 64-6198, produces a discriminative stimulus in rats distinct from that of a mu, kappa and delta opioid receptor agonist cue. J Pharmacol Exp Ther 311:652-658
31. Redrobe JP, Calo G, Regoli D, Quirion R (2002) Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn Schmiedebergs Arch Pharmacol 365:164-167
32. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O (1995) Orphanin FQ: a neuropeptide that activates an opioid like G protein-coupled receptor. Science 270:792-794
33. Rizzi D, Bigoni R, Rizzi A, Jenck F, Wichmann J, Guerrini R, Regoli D, Calo G (2001) Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues. Naunyn Schmiedebergs Arch Pharmacol 363:551-555
34. Rodgers RJ (1997) Animal models of 'anxiety': where next? Behav Pharmacol 8:477-496
35. Silva AJ, Simpson EM, Takahashi JS, Lipp H-P, Nakanishi S, Wehner JM, Geise KP, Tully T, Abel T, Chapman PF, Fox K, Grant S, Itahora S, Lathe R, Mayford M, McNamara JO, Morris RJ, Piciotto M, Roder J, Shin H-S, Slesinger PA, Storm DR, Stryker MP, Tonegawa S, Wang Y, Wolfer DP (1997) Mutant mice and neuroscience: recommendations concerning genetic background. Banbury conference on genetic background in mice. Neuron 19:755-759
36. Smith PA, Moran TD (2001) The nociceptin receptor as a potential target in drug design. Drug News Perspect 14:335-345
37. Snyder SH, Pasternak GW (2003) Historical review: opioid receptors. Trends Pharmacol Sci 24:198-205
38. Sulaiman MR, Niklasson M, Tham R, Dutia MB (1999) Modulation of vestibular function by nociceptin/orphanin FQ: an in vivo and in vitro study. Brain Res 828:74-82
39. Varty GB, Pond A, Hodgson R, Grzelak M, Guthrie D, Lu S, Morgan C, Higgins GA (2003) Determination of the anxiolytic vs. side-effect profile of a nociceptin NOP1 agonist and metabotrophic mGluR5 antagonists using rodent models of anxiety and neurological function. Soc Neurosci Abstr 29:959.11
40. Wichmann J, Adam G, Rover S, Hennig M, Scalone M, Cesura AM, Dautzenberg FM, Jenck F (2000) Synthesis of 1S,3aS.-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1- yl.-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one, a potent and selective orphanin FQ receptor agonist with anxiolytic-like properties. Eur J Med Chem 35:839-851